teicoplanin

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: teicoplanin
• 英文别名: teicoplanin A₂-3；(1S,2R,19R,22R,34S,37R,40R,52S)-2-[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-azaniumyl-5,15-dichloro-64-[(2S,3R,4R,5S,6R)-3-(decanoylamino)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-26,31,44,49-tetrahydroxy-21,35,38,54,56,59-hexaoxo-47-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7,13,28-trioxa-20,36,39,53,55,58-hexazaundecacyclo[38.14.2.23,6.214,17.219,34.18,12.123,27.129,33.141,45.010,37.046,51]hexahexaconta-3,5,8,10,12(64),14,16,23(61),24,26,29(60),30,32,41(57),42,44,46(51),47,49,62,65-henicosaene-52-carboxylate
• 化学式: C₈₈H₉₇Cl₂N₉O₃₃
• 分子量: 1879.68
• InChiKey: BJNLLBUOHPVGFT-PKMGYIMSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  132
• 可旋转键数：
  20
• 环数：
  16.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  662
• 氢给体数：
  24
• 氢受体数：
  34

反应信息

• 作为产物：
  描述：

  N-[5-[[(3-氨基-3-亚氨基丙基)氨基]羰基]-1-甲基-1H-吡咯-3-基]-2-(甲酰氨基)-4-噻唑甲酰胺 、 teicoplanin pseudoaglycone 在 N-acyltransferase Orf₁₁ 作用下， 以 aq. buffer 为溶剂， 反应 6.0h， 生成 teicoplanin
  参考文献：
  名称：

  Multiple Complexes of Long Aliphatic N-Acyltransferases Lead to Synthesis of 2,6-Diacylated/2-Acyl-Substituted Glycopeptide Antibiotics, Effectively Killing Vancomycin-Resistant Enterococcus

  摘要：

  Teicoplanin A2-2 (Tei)/A40926 is the last-line antibiotic to treat multidrug-resistant Gram-positive bacterial infections, e.g., methicillinresistant Staphylococcus aurcus (MRSA) and vancomycin-resistant enterococcus (VRE). This class of antibiotics is powered by the N-acyltransferase (NAT) Orf11*/Dbv8 through N-acylation on glucosamine at the central residue of Tei/A40926 pseudoaglycone. The NAT enzyme possesses enormous value in untapped applications; its advanced development is hampered largely due to a lack of structural information. In this report, we present eight high-resolution X-ray crystallographic unary, binary, and ternary complexes in order to decipher the molecular basis for NAT's functionality. The enzyme undergoes a multistage conformational change upon binding of acyl-CoA, thus allowing the uploading of Tei pseudoaglycone to enable the acyl-transfer reaction to take place in the occlusion between the N- and C-halves of the protein. The acyl moiety of acyl-CoA can be bulky or lengthy, allowing a large extent of diversity in new derivatives that can be formed upon its transfer. Vancomycin/synthetic acyl-N-acetyl cysteamine was not expected to be able to serve as a surrogate for an acyl acceptor/donor, respectively. Most strikingly, NAT can catalyze formation of 2-N,6-O-diacylated or C6 -> C2 acyl-substituted Tei analogues through an unusual 1,4-migration mechanism under stoichiometric/solvational reaction control, wherein selected representatives showed excellent biological activities, effectively counteracting major types (VanABC) of VRE.

  DOI：

  10.1021/ja504125v

文献信息

• GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY
  申请人：Rafai Far Adel

  公开号：US20120149632A1

  公开（公告）日：2012-06-14

  The invention relates to derivatives of glycopeptide and lipoglycopeptide antibiotics possessing an altered ionization state with respect to the parent glycopeptide or lipoglycopeptide antibiotic, and having the ability to be regenerated as the parent glycopeptide or lipoglycopeptide antibiotic under physiological conditions. These compounds are useful as antibiotics for the prevention and/or the treatment of bacterial infections.

  这项发明涉及具有与母体糖肽或脂质糖肽抗生素相比具有改变的电离状态的糖肽和脂质糖肽抗生素衍生物，并且具有在生理条件下能够再生为母体糖肽或脂质糖肽抗生素的能力。这些化合物可用作预防和/或治疗细菌感染的抗生素。
• ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES
  申请人：GENENTECH, INC.

  公开号：US20150366985A1

  公开（公告）日：2015-12-24

  The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.

  这项发明提供了抗壁母细胞酸抗体及其抗生素结合物，以及使用它们的方法。
• PHOSPHONATED GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS
  申请人：Tanaka Kelly

  公开号：US20100113333A1

  公开（公告）日：2010-05-06

  The present invention is directed to antimicrobial compounds which have an affinity for binding bones. More particularly, the invention is directed to phosphonated derivatives of glycopeptide or lipoglycopeptide antibiotics. These compounds are useful as antibiotics for the prevention or treatment of bone and joint infections, especially for the prevention and treatment of osteomyelitis.

  本发明涉及具有与骨骼结合亲和力的抗微生物化合物。更具体地，该发明涉及磷酸酯化的糖肽类或脂质糖肽类抗生素的衍生物。这些化合物可用作抗生素，用于预防或治疗骨骼和关节感染，特别是用于预防和治疗骨髓炎。
• SELECTIVE OXIDATION OF C-H BONDS OF MODIFIED SUBSTRATES BY P450 MONOOXYGENASE
  申请人：Li Shengying

  公开号：US20120190635A1

  公开（公告）日：2012-07-26

  The present invention provides regio- and stereoselective oxidation of unactivated C—H bonds using an engineered mutant cytochrome P450 monooxygenase and an engineered substrate.

  本发明提供了使用经过改造的突变型细胞色素P450单氧酶和经过改造的底物对非活化的C-H键进行区域和立体选择性氧化的方法。
• Methods of inhibiting and treating biofilms using glycopeptide antibiotics
  申请人：Neesham-Grenon Eve

  公开号：US10201587B2

  公开（公告）日：2019-02-12

  The present invention is directed to methods of inhibition, delay of formation, treatment, prophylaxis and/or prevention of infections caused by bacteria that exhibit tolerance to antimicrobial agents, including slow growing, stationary-phase and biofilm forming bacteria, through the use of glycopeptide antibiotics, such as oritavancin.

  本发明涉及使用糖肽类抗生素，例如奥利他万星，来抑制、延迟、治疗、预防和/或预防由耐抗微生物菌引起的感染的方法，包括生长缓慢、静止期和生物膜形成菌。